France· FR:66263258
INCRELEX 10 mg/ml, solution injectable
A medicinal product containing mécasermine recombinante, registered in France by ESTEVE PHARMACEUTICALS (ESPAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉCASERMINE RECOMBINANTE
- Manufacturer
- ESTEVE PHARMACEUTICALS (ESPAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009381467761 flacon(s) en verre de 4 mlEUR 600.3
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mécasermine recombinante in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandIncrelex 10 mg/ml solution for injectionEsteve Pharmaceuticals S.A.
- NetherlandsIncrelex 10 mg/ml, oplossing voor injectieEsteve Pharmaceuticals S.A.
- United StatesIncrelexIpsen Biopharmaceuticals, Inc.
- CanadaINCRELEXIPSEN BIOPHARMACEUTICALS CANADA INC
- CzechiaINCRELEXEsteve Pharmaceuticals S.A., Barcelona
- SpainINCRELEX 10 mg/ml SOLUCION INYECTABLEEsteve Pharmaceuticals S.A.
- FinlandIncrelexEsteve Pharmaceuticals, S.A
- United KingdomIncrelex 40mg/4ml solution for injection vialsEsteve Pharmaceuticals Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Increlex
- Liechtenstein · Increlex
- Norway · Increlex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/86d9f5b7-0d7b-449a-ab41-935947963bc6 GET /v1/drugs/86d9f5b7-0d7b-449a-ab41-935947963bc6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66263258",
"date_amm": "2007-08-03",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/07/402",
"substance": "MÉCASERMINE RECOMBINANTE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about mécasermine recombinante.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.